Cost- Effectiveness of Deep Molecular Response with First- Line Nilotinib vs. Imatinib in PH+ Chronic Myeloid Leukaemia Measured by Effectively Treated Patient- Years in Bulgaria
Borissov, BNVolume:
21
Journal:
Value in Health
DOI:
10.1016/j.jval.2018.07.830
Date:
September, 2018
File:
PDF, 61 KB
2018